托珠单抗治疗类风湿关节炎患者出现外周溃疡性角膜炎:矛盾反应还是疗效不足?
该病例系列报告了4例(6眼)接受托珠单抗(TCZ)治疗的类风湿关节炎(RA)患者出现外周溃疡性角膜炎(PUK),年龄47-62岁,PUK发生时RA中位病程13年、TCZ中位治疗9个月;2例疾病活动(DAS28>3.2)、2例疾病控制(DAS28≤3.2)。所有患者初期更换免疫调节治疗,2例 later 重新引入TCZ未复发;角膜炎症均获控制,1眼严重视力丧失。结论认为PUK可发生于长期RA患者换用TCZ后,依背景可解释为疗效不足或矛盾表现。
要点
- 长期RA患者换用TCZ后可能发生PUK,需警惕眼部炎症。
- PUK发生时RA疾病活动度可高可低,并非均与活动相关。
- 停用TCZ并局部联合全身治疗可控制角膜炎症,部分可再试用TCZ。
核心结论
- PUK可发生于长期RA患者换用TCZ后,依背景可解释为疗效不足或矛盾表现。
研究设计与样本
- 病例系列,纳入4例(6眼)接受TCZ治疗的RA患者,年龄47-62岁,报告眼科与全身表现并讨论机制。
主要发现
- PUK发生时RA中位病程13年(IQR 3-13),TCZ中位治疗9个月(IQR 3-14)。
- 2例RA活动(DAS28>3.2),2例RA控制(DAS28≤3.2)。
- 所有患者初期更换免疫调节治疗,2例 later 重新引入TCZ未出现PUK复发。
- 角膜炎症经局部和全身治疗均获控制,1眼出现严重视力丧失。
临床怎么用
- 对TCZ治疗的RA患者出现眼部炎症时,应评估PUK并区分疗效不足与矛盾反应。
- PUK发生后可考虑更换免疫调节治疗,角膜炎症控制后部分患者可谨慎再试用TCZ。
局限性
- 病例系列样本量小(4例),无法确立因果关系或发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Peripheral ulcerative keratitis (PUK) is a severe corneal condition associated with uncontrolled RA. Tocilizumab (TCZ) is used to control RA, however, episodes of paradoxical ocular inflammation have been reported in TCZ-treated patients. We report a case series of PUK in TCZ-treated RA patients with ophthalmological and systemic findings and discuss the potential underlying mechanisms. METHODS: Four patients (six eyes), 47-62 years of age, were included. At the onset of PUK, the median duration of RA was 13 years [interquartile range (IQR) 3-13] and the median treatment with TCZ was 9 months (IQR 3-14). Two patients had active disease [28-joint DAS (DAS28) >3.2] and the disease was controlled in two patients (DAS28 ≤3.2). RESULTS: TCZ was initially replaced by another immunomodulatory treatment in all patients and later reintroduced in two patients without PUK recurrence. Corneal inflammation was controlled in all cases with local and systemic treatments, with severe visual loss in one eye. CONCLUSION: PUK may occur in patients with long-standing RA after a switch to TCZ and can be interpreted, depending on the context, as insufficient efficacy or a paradoxical manifestation. These cases highlight the urgent need for reliable biomarkers of the efficacy and paradoxical reactions of biologics.
引用
- Cohen F, Gabison EE, Stéphan S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy? Rheumatology (Oxford). 2021. PMID: 33528012. doi:10.1093/rheumatology/keab093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。